Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704050 · ClinicalTrials.gov registry record · Phase 4
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence
A Phase 4 study, sponsored by Tulane University School of Medicine.
- Terminated
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT04704050 is a Phase 4 study that was terminated before completion, run by Tulane University School of Medicine. The registered enrollment target is 22 participants.
The verdict
NCT04704050, a Phase 4 study, was terminated before completion, sponsored by Tulane University School of Medicine.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two trial groups.
Interventions
- DRUG Placebo
- DRUG dronedarone 400 mg Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04704050
The ClinicalTrials.gov registry entry for NCT04704050 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04704050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04704050 about?
NCT04704050 is a clinical study titled "Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence". Patients who have undergone cardiac ablation will be randomized and blinded to one of two groups; one group will receive dronedarone while the other group will receive a placebo. The incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be analyzed between the two...
What is the current status of trial NCT04704050?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2021-05-15. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04704050?
The interventions under investigation include: Placebo (DRUG), dronedarone 400 mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04704050?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.